* If you want to update the article please login/register
A week to week, face-to-face twice a week for 8 weeks will be held for the 1st group within the scope of diabetic foot training, and an exercise programme aimed at increasing the mobility and strength of the foot will be introduced through video calls twice a week. For 8 weeks, the 2nd group will be given a booklet describing this work, and they will be followed by video calls 1 day a week for 8 weeks. Foot and foot anatomy, foot anatomy, and epidemiology, diabetic foot disorders, epidemiology, diabetes, epidemiology, and epidemiology, pain causes will be discussed and treated, ergonomics, exercises to be done, sensory education, and foot care are among the topics to investigate in diabetic foot school education, risky situations, foot care, foot care, and foot care will be discussed. Individuals in the 2nd group of the study will be included in the diabetic foot school instruction based on their wishes. With Rsscan pedobarography, Plantar pressures during walking can be assessed. Individuals' diabetic foot knowledge will be evaluated face to face with the diabetic foot knowledge scale, foot self-care tools, diabetic foot self-care questionnaire, and a foot care behavior scale.
Source link: https://clinicaltrials.gov/ct2/show/NCT05431660
Patients with diabetic foot in the Endocrinology clinic and polyclinic of the University Hospital will be included in the study. Patients who comply with the study's inclusion criteria and consent to participate in the study will be included in the sample. The sample will include patients who meet the study's criteria and promise to participate in the study. The patient questionnaire, the Diabetic Foot Self-Care Questionnaire, and the Foot Care Behavior Scale were used to gather data, according to the researchers who searched the literature. The Turkish scale items will be re-English, and the linguist's assertion that the scale will be used will be taken. The Turkish scale items will be translated back into English, and the linguist's statement that the scale can be used will be taken. The Kaiser Meyer Olkin Test, which measures the adequacy of sample size as antecedent samples, will be used by investigators, and Bartlett's Test For Sphericity will be used to determine sphericity.
Source link: https://clinicaltrials.gov/ct2/show/NCT05404178
Diabetes' prevalence and complications with age continue to increase with age. Diabetic foot ulcers are costly to treat, can take a long time to heal, and contribute to a decrease in patient quality of life. Patients are still vulnerable to getting more foot ulcers as time goes. This initiative aims to reduce the time it takes to heal a diabetic foot ulcer, extend the time between episodes of ulceration, and increase diabetic foot ulcer patients' quality of life.
Source link: https://clinicaltrials.gov/ct2/show/NCT05094037
This study was designed as a prospective case-control research to determine the impact of PRF application on wound healing in diabetic foot ulcers. Patients with diabetic foot wounds who applied to Bolu Home Health Services affiliated with the Republic of Turkey's Ministry of Health and Senior Health Directorate, as well as patients who were followed up in Bolu's downtown area will be included in the study. According to the randomization results of the scheme, the patients in the first column will be the experimental group, and the patients in the second column will be the control group. If the patient is in the experimental group, PRF will be applied to the diabetic foot wound, and in the control group, classic wound dressing will be used. From the patients participating in the experiment, the blood from the patients will be injected into a tube without anticoagulant use with an injector or a vacutainer directly from the patient. The tube will be removed from the unit after this process, and the PRF clot that had risen in the middle of the tube will be removed with forceps. Classic Wound Dressing Application: In the control group, the researcher's research showed that classical dressing would be applied to the diabetic foot wound of the patients. Both feet will be evaluated in terms of diabetic foot using the 'Diabetic Foot Evaluation Form,'.
Source link: https://clinicaltrials.gov/ct2/show/NCT05483777
This research is a twelve-week single-center, controlled, double-blind review of the risk and success of a folic acid wound treatment versus Placebo in the promotion of healing of chronic, early stage diabetic foot ulcer wound wounds. Cell death rates in wound keratinocytes from non-healing DFUs rises due to significant transcription factor activation. Folinic acid calcium salt is the bioactive component of folic acid that does not require reduction by dihydrofolate reductase. Experimental results of topical folinic acid show significant improvements in wound healing parameters, reduced cellular markers of inflammation and increased active signaling of tissue repair. FAWT's topical administration has ruled out the risk of elevated blood folate levels in oral high dose folic acid, which may include an increase in the occurrence of sub-classes of colon or prostate cancer. The Screening Phase of the study is intended to determine if male and female Veterans selected as research participants are eligible to continue to the Treatment Phase of the study. Participants from the four-week Screening Phase will be randomly assigned to either the FAWT or Placebo group of fifteen people per month. Following the complete closure of the wound or after twelve weeks of therapy, Paired marginal wound tissue biopsies will be obtained at two points of the Treatment Phase: 1 at the start of the phase and 2 following complete closure of the wound or after twelve weeks of treatment.
Source link: https://clinicaltrials.gov/ct2/show/NCT04723134
BACKGROUND: Patients in about 80% of diabetes-related lower extremity amputations suffer from a foot ulcer, often caused by lower extremity arterial disease. diabetic patients with foot ulcers often need lower leg amputation due to reduced extremity arterial disease and lower extremity arterial disease. The most important factor in repairing the diabetic foot ulcer is the arterial supply to the ulcer, which also minimizes the risk of amputation. In patients with low-grade arterial disease of the lower legs and diabetic foot ulcers, immediate revascularization results in less cardiovascular problems and amputations, as well as improved ulcer healing, as well as improved ulcer healing, according to the new standard of care. Study design: Participants will be randomly assigned either the control arm or the active arm after being included in the study. In the control arm standard wound care will be carried out.
Source link: https://clinicaltrials.gov/ct2/show/NCT04939038
Wound Selection Only one wound per subject will be included in the analysis. Each wound will be measured for volume in subjects with multiple wounds. Blinding and Blinding Procedures Prior to study launch, Active and Control samples will be packaged and labeled as A or B, although randomization envelopes will be distributed to the study staff and used to obtain randomization assignments. The subjects' wound will be debrided and dressed with SOC after a run-in inspection. The study staff will use randomization number labels and sock assignment of socks A or B enclosed in the envelope. On the CRF, the randomization number and the treatment assignment letter will be noted by the research staff. The key, indicating therapy assignments, will only be open to employees not directly involved in the study until after the subject's completion of study activities. Select the target ulceration, duration of the target ulcer, and current treatment methods. Wounds will be both approved and offloaded by physician discretion, as determined by each individual. Subjects who qualify for the run-in are required to refrain from using banned medications and return to the office for Run-in Visit 2 within 7 days. If wound size rises/decreases by 30% or more, the patient will be deemed a screen failure and removed from the study. If wound size decreases by less than 30%, the patient wound will be treated with the highest level of care and return for run-in Week 2 Run-In Within 7 days. Patients will be randomized to either the Celliant Active or Control treatment arm if wound size rises/decreases by less than 30%. The study's progress was tracked through the week, and the day/night was worn throughout the week. Document study compliance from the subject Amount of time the sock was worn throughout the week The sock was worn during the week/night? Wound Closed 2 weeks At 2 weeks apart, the evaluating doctor's findings have been confirmed as closed after complete skin re-epithelialization without drainage or dressing requirements that was not specified by the evaluating physician. Study Visit 12/EOS If the research wound closes before the 12-week mark, the participants will go to EOS visit at the time of wound closure. After the week 12 wound assessment, a subject whose wound does not completely close by week 12 will leave the study. Document review compliance information from the subject Amount of time the sock was worn throughout the week Amount of time the sock was worn throughout the week Was it worn during the day or night? Perform pain evaluation Ask the patient if they were in the active or control group Administer DFS-SF Collect all relevant concomitant medications Redress the wound according to a physician-directed standard of care. Study Visit Follow Up If the subject's wound closes within the 12-week healing window, they will then begin the follow-up phase of the study. Examine the study foot for new sites of ulceration iii.
Source link: https://clinicaltrials.gov/ct2/show/NCT04709419
An independent adjudication commission made up of wound care experts will oversee the trial, ensuring that wound healing assessment and confirmation of wound healing will be led by an independent adjudication committee. Arm 1: The SOC's treatment arm in this research is offloading of the DFU, appropriate sharp or surgical debridement, infection control, and wound care coating with biocompliant resorbable glass fiber dressing, MIRRAGENu2122Advanced Wound Matrix, soft roll, and compressive wrap.
Source link: https://clinicaltrials.gov/ct2/show/NCT03398538
Subjects who were randomly chosen to receive V. A. C. will be compared to that of the average time it takes to complete wound bed preparations between Subjects randomly chosen to receive V. A. C.
Source link: https://clinicaltrials.gov/ct2/show/NCT00837096
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions